Browsing by Author "Llanos M., Carolina"

Now showing items 1-4 of 4

    • Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y ... 
      Llanos M., Carolina; Soto Sáez, Lilian; Sabugo Siraqyan, María Francisca; Bastías Ch., M. José; Salazar A., Lorena; Aguillón Gutiérrez, Juan Carlos; Cuchacovich Turteltaub, Miguel (Sociedad Médica de Santiago, 2005)
      Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects 0.8% of the world population, it affects the synovial membrane of joints and the clinical presentation encompasses a wide spectrum, ranging from a ...
    • Prosthetic joint infections Infecciones en prótests articulares 
      Fica Cubillos, Alberto; Llanos M., Carolina; Luzoro Vial, Amaranta; Barrera, Carlos de la; Gabriel Miranda, U. (2000)
      A retrospective study was performed to characterize hip and knee prosthetic joint infections. Cases were identified from discharge records available from 1993. Nineteen prosthetic joint infection episodes were identified ...
    • Terapias emergentes en artritis reumatoide 
      Aguillón Gutiérrez, Juan Carlos; Cruzat C., Andrea; Contreras Levicoy, Juan; Dotte G., Andrés; Pesce Reyes, Bárbara; Aravena M., Octavio; Salazar A., Lorena; Catalán Martina, Diego; Abello Cáceres, Paula; Aguirre D., Adam; Llanos M., Carolina; Cuchacovich Turteltaub, Miguel (Sociedad Médica de Santiago, 2005)
      The use of biological agents such as etanercept, infliximab, adalimumab and anakinra has been recently approved for the treatment of rheumatoid arthritis. All are effective controlling signs and symptoms and inhibiting ...
    • Uso de rituximab (anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: ... 
      Sabugo Siraqyan, María Francisca; Llanos M., Carolina; Soto Sáez, Lilian; Gutiérrez, Jorge; Cuchacovich Turteltaub, Miguel (Sociedad Médica de Santiago, 2005)
      New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus ...